[HTML][HTML] Tyk2 targeting in immune-mediated inflammatory diseases

L Rusiñol, L Puig - International journal of molecular sciences, 2023 - mdpi.com
The Janus kinase (Jak)/signal transducer and activating protein (STAT) pathways mediate
the intracellular signaling of cytokines in a wide spectrum of cellular processes. They …

Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019–2021)

F Gonzalez Lopez de Turiso… - Expert Opinion on …, 2022 - Taylor & Francis
ABSTRACT Introduction Tyrosine kinase 2 (TYK2) is a member of the JAK family class of
kinases that is responsible for mediating the immune response to IL-12, IL-23, and IFNα. The …

[HTML][HTML] Novel small molecule tyrosine kinase 2 pseudokinase ligands block cytokine-induced TYK2-mediated signaling pathways

Y Zhou, X Li, R Shen, X Wang, F Zhang, S Liu… - Frontiers in …, 2022 - frontiersin.org
A member of the Janus kinase (JAK) family, Tyrosine Kinase 2 (TYK2), is crucial in
mediating various cytokine-signaling pathways such as interleukin-23 (IL23), interleukin-12 …

TYK2 in immune responses and treatment of psoriasis

L Shang, J Cao, S Zhao, J Zhang… - Journal of Inflammation …, 2022 - Taylor & Francis
Abstract Tyrosine kinase 2 (TYK2), a key part of the Janus kinase-signal transducer and
activator of transcription (JAK-STAT) pathway, plays an integral role in the differentiation and …

TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases

M Gonciarz, K Pawlak-Buś, P Leszczyński… - …, 2021 - Taylor & Francis
JAKs are intracellular protein tyrosine kinases that, through activation of STATs, are
responsible for signal transduction pathways that regulate cellular responses to numerous …

[HTML][HTML] Allosteric TYK2 inhibition: Redefining autoimmune disease therapy beyond JAK1-3 inhibitors

LT Jensen, KE Attfield, M Feldmann, L Fugger - EBioMedicine, 2023 - thelancet.com
JAK inhibitors impact multiple cytokine pathways simultaneously, enabling high efficacy in
treating complex diseases such as cancers and immune-mediated disorders. However, their …

TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases

K Ghoreschi, M Augustin, X Baraliakos… - JDDG: Journal der …, 2021 - Wiley Online Library
Immune‐mediated chronic inflammatory diseases have emerged as a leading cause of
morbidity and mortality in Western countries over the last decades. Although multiple …

[HTML][HTML] Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases

Z Fang, H Sun, Y Wang, Z Sun, M Yin - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Abstract Tyrosine kinase 2 (TYK2) as a member of Janus kinase (JAK) family, mainly
mediates the signaling of type I interferons (IFN), interleukin-12 (IL-12) and interleukin-23 (IL …

TYK2: an emerging therapeutic target in rheumatic disease

E Morand, JF Merola, Y Tanaka, D Gladman… - Nature Reviews …, 2024 - nature.com
Abstract Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family of intracellular
signalling molecules. By participating in signalling pathways downstream of type I …

Therapeutic potential of tyrosine kinase 2 in autoimmunity

Y Liang, Y Zhu, Y Xia, H Peng, XK Yang… - Expert Opinion on …, 2014 - Taylor & Francis
Introduction: Tyrosine kinase 2 (Tyk2) is a Janus kinase family member that is crucial for
signaling transduction in response to a wide variety of cytokines, including type I IFNs, IL-6 …